Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis (Nasdaq: ARQT) will present new clinical and long-term caregiver-reported data for its marketed ZORYVE (roflumilast) portfolio at the 2026 American Academy of Dermatology Annual Meeting, March 27–31 in Denver. Key presentations include a late-breaking podium on the INTEGUMENT-INFANT Phase 2 trial (infants 3–<24 months) and Phase 3 subgroup and PASI results from STRATUM, DERMIS-1/2, ARRECTOR, and INTEGUMENT-OLE (ages 2–5).
The program includes a late-breaking podium (Mar 28), a 5-minute poster (Mar 27), and multiple e-posters available beginning Mar 27.
Arcutis (Nasdaq: ARQT) reported long-term Phase 3 open-label extension data for ZORYVE cream 0.05% in children ages 2–5 with mild-to-moderate atopic dermatitis, showing durable and improving efficacy through 56 weeks and a favorable safety/tolerability profile.
Key results: 63.1% achieved vIGA-AD Clear/Almost Clear at Week 56; EASI-75 reached 71.9–76.0% at Week 56; median disease-control duration on twice-weekly proactive dosing ~238 days. Overall TEAEs were mostly mild/moderate; SAEs 3.2% (none treatment-related).
Arcutis (Nasdaq: ARQT) promoted Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary effective March 5, 2026. He will continue to lead legal, compliance, governance, IP protection and support corporate transactions as the company commercializes the ZORYVE portfolio and advances its pipeline.
Mr. Matsuda joined Arcutis in January 2022 and is credited with guiding the company through six FDA approvals of ZORYVE while scaling legal and compliance functions.
Arcutis (Nasdaq: ARQT) has begun enrolling the first participant in a Phase 1a/1b first‑in‑human study (ARQ-234-131) of ARQ-234, a CD200R agonist fusion protein for moderate to severe atopic dermatitis.
The double‑blind, randomized, placebo‑controlled study will assess safety and tolerability in single‑ascending and multiple‑ascending dose cohorts in healthy volunteers and adults with atopic dermatitis, plus a small proof‑of‑concept cohort. ARQ-234 is administered subcutaneously and is designed to selectively activate CD200R to modulate overactive immune responses.
Arcutis (Nasdaq: ARQT) announced management will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company will host a Fireside Chat on March 2, 2026 at 1:50 p.m. ET.
The live webcast is available via the company Events page and a replay will remain accessible on the Arcutis website for 180 days following the conference.
Arcutis (Nasdaq: ARQT) reported strong commercial momentum for ZORYVE with Q4 2025 net product revenue of $127.5M (up 84% YoY, +29% sequential) and full-year 2025 net product revenue of $372.1M (up 123% YoY). The company generated $26.2M operating cash flow in Q4, raised 2026 net product sales guidance to $480–$495M, and expects an sNDA submission for ZORYVE cream 0.05% in infants in Q2 2026.
Arcutis also expanded its dermatology sales force, secured broader Medicare access, and holds cash and marketable securities of $221.3M as of Dec 31, 2025.
Arcutis (Nasdaq: ARQT) announced that professional golfer Max Homa joined its Free to Be Me awareness campaign to encourage people with seborrheic dermatitis to seek long-term treatment. The company highlights ZORYVE foam 0.3%, indicated for ages 9+, showing rapid clearance and itch relief in clinical trials.
In trials, 77% achieved clear/almost clear skin at 8 weeks versus 53% for inactive foam; itch relief reached nearly 63% versus 41%. ZORYVE is steroid-free, leave-in, and reported common side effects ≥1% (common cold, nausea, headache).
Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement awards: an aggregate of 94,000 restricted stock units granted to 12 newly hired employees with a grant date of February 2, 2026. The RSUs vest over four years with 25% vesting on each annual anniversary and were approved by the Compensation Committee under the 2022 Inducement Plan, disclosed in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis (Nasdaq: ARQT) reported positive topline results from the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% (roflumilast) in infants 3 months to 24 months with mild–moderate atopic dermatitis. At Week 4, . The cream was well tolerated with no new safety signals through four weeks. The company plans an sNDA submission in Q2 2026 for this age group.
Arcutis (Nasdaq: ARQT) announced on January 23, 2026 that it and Kowa mutually agreed to terminate their promotion agreement for ZORYVE promotion to primary care physicians and pediatricians in the U.S.
Arcutis will assume responsibility for sales and promotion to those clinicians, is finalizing promotional plans, and will provide further detail on the Q4 earnings call on February 25, 2026. Under the termination, Kowa will stop promotion and Arcutis will not be required to make any further payments. The company expects to remain cash flow break even and does not expect the change to negatively affect 2026 net product sales guidance.